Research programme: cancer therapeutics - Endocyte

Drug Profile

Research programme: cancer therapeutics - Endocyte

Alternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC 2629; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Depsipeptides; Doxorubicins; Drug conjugates; Folic-acids; Oligopeptides; Small molecules; Taxanes
  • Mechanism of Action Folate receptor 1 antagonists; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Feb 2018 EC 2629 is still in non-clinical development for Solid tumours in USA (Endocyte website, Feb 2018)
  • 09 Feb 2018 EC 2629 is available for licensing as of 09 Feb 2017. http://endocyte.com/technology/partnering/
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top